Endocrine causes of nonalcoholic fatty liver disease

被引:65
作者
Marino, Laura [1 ]
Jornayvaz, Francois R. [1 ]
机构
[1] Univ Lausanne Hosp, Serv Endocrinol Diabet & Metab, CH-1011 Lausanne, Switzerland
关键词
Endocrine diseases; Nonalcoholic fatty liver disease; Insulin resistance; Obesity; Type; 2; diabetes; RENIN-ANGIOTENSIN SYSTEM; POLYCYSTIC-OVARY-SYNDROME; GROWTH-FACTOR; 21; HORMONE-BINDING GLOBULIN; 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE-1; ALANINE AMINOTRANSFERASE ACTIVITY; IMPROVES INSULIN SENSITIVITY; SERUM ADIPOKINE LEVELS; HEPATIC STEATOSIS; METABOLIC SYNDROME;
D O I
10.3748/wjg.v21.i39.11053
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the industrialized world. The prevalence of NAFLD is increasing, becoming a substantial public health burden. NAFLD includes a broad spectrum of disorders, from simple conditions such as steatosis to severe manifestations such as fibrosis and cirrhosis. The relationship of NAFLD with metabolic alterations such as type 2 diabetes is well described and related to insulin resistance, with NAFLD being recognized as the hepatic manifestation of metabolic syndrome. However, NAFLD may also coincide with endocrine diseases such as polycystic ovary syndrome, hypothyroidism, growth hormone deficiency or hypercortisolism. It is therefore essential to remember, when discovering altered liver enzymes or hepatic steatosis on radiological exams, that endocrine diseases can cause NAFLD. Indeed, the overall prognosis of NAFLD may be modified by treatment of the underlying endocrine pathology. In this review, we will discuss endocrine diseases that can cause NALFD. Underlying pathophysiological mechanisms will be presented and specific treatments will be reviewed.
引用
收藏
页码:11053 / 11076
页数:24
相关论文
共 294 条
[11]   Adiponectin and alcoholic fatty liver: Is it, after all, about what you eat? [J].
Anania, FA .
HEPATOLOGY, 2005, 42 (03) :530-532
[12]   HEPATIC-EFFECTS OF DIETARY WEIGHT-LOSS IN MORBIDLY OBESE SUBJECTS [J].
ANDERSEN, T ;
GLUUD, C ;
FRANZMANN, MB ;
CHRISTOFFERSEN, P .
JOURNAL OF HEPATOLOGY, 1991, 12 (02) :224-229
[13]   Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease [J].
Angulo, P ;
Alba, LM ;
Petrovic, LM ;
Adams, LA ;
Lindor, KD ;
Jensen, MD .
JOURNAL OF HEPATOLOGY, 2004, 41 (06) :943-949
[14]   Metabolic syndrome and nonalcoholic fatty liver disease: Is insulin resistance the link? [J].
Asrih, Mohamed ;
Jornayvaz, Francois R. .
MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2015, 418 :55-65
[15]   Ketogenic Diet Impairs FGF21 Signaling and Promotes Differential Inflammatory Responses in the Liver and White Adipose Tissue [J].
Asrih, Mohamed ;
Altirriba, Jordi ;
Rohner-Jeanrenaud, Francoise ;
Jornayvaz, Francois R. .
PLOS ONE, 2015, 10 (05)
[16]   Diets and nonalcoholic fatty liver disease: The good and the bad [J].
Asrih, Mohamed ;
Jornayvaz, Francois R. .
CLINICAL NUTRITION, 2014, 33 (02) :186-190
[17]   The regulation of human P450c17 activity: Relationship to premature adrenarche, insulin resistance and the polycystic ovary syndrome [J].
Auchus, RJ ;
Geller, DH ;
Lee, TC ;
Miller, WL .
TRENDS IN ENDOCRINOLOGY AND METABOLISM, 1998, 9 (02) :47-50
[18]  
Averna M, 2015, ATHEROSCLEROSIS SUPP, V17, P27, DOI 10.1016/S1567-5688(15)50007-X
[19]   Effects of Testosterone Undecanoate on Cardiovascular Risk Factors and Atherosclerosis in Middle-Aged Men with Late-Onset Hypogonadism and Metabolic Syndrome: Results from a 24-month, Randomized, Double-Blind, Placebo-Controlled Study [J].
Aversa, Antonio ;
Bruzziches, Roberto ;
Francomano, Davide ;
Rosano, Giuseppe ;
Isidori, Andrea M. ;
Lenzi, Andrea ;
Spera, Giovanni .
JOURNAL OF SEXUAL MEDICINE, 2010, 7 (10) :3495-3503
[20]   NONALCOHOLIC STEATOHEPATITIS - AN EXPANDED CLINICAL ENTITY [J].
BACON, BR ;
FARAHVASH, MJ ;
JANNEY, CG ;
NEUSCHWANDERTETRI, BA .
GASTROENTEROLOGY, 1994, 107 (04) :1103-1109